|
|
|
|
|
SAN DIEGO, Feb 19, 2020 - (ACN Newswire) - DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation - JLABS @ Shanghai, announced today that it has entered into a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson*. Under terms of the agreement, the Lung Cancer Initiative has taken an exclusive license to research, develop and commercialize novel molecules from within the DNX portfolio. Financial terms of the collaboration were not disclosed.
"We are delighted to be collaborating with the Lung Cancer Initiative at Johnson & Johnson," said Rajiv Datar, Ph.D., co-founder and CEO of DNX. "We look forward to progressing DNX's novel molecules into clinical development."
"Our collaboration with the Lung Cancer Initiative at Johnson & Johnson was fostered by being an awardee of the Lung Cancer Innovation QuickFire Challenge and receiving residency at Johnson & Johnson Innovation - JLABS @ Shanghai," commented Dr. Carl Edwards III, CSO of DNX. "We are now looking forward to establishing our Asia-Pacific Research and Development capabilities in Shanghai, which will be wholly dedicated to Cancer Immunotherapy."
About DNX Biopharmaceuticals, Inc.
Founded in 2014 and headquartered in San Diego, California, USA, DNX is a biopharmaceutical company developing non-immunogenic, long-acting biologic therapies for the treatment of patients with life-long diseases linked to inflammation, autoinflammation and oncology. As an awardee of the Lung Cancer Innovation QuickFire Challenge, DNX received residency at Johnson & Johnson Innovation - JLABS @ Shanghai. At JLABS Shanghai, DNX will pursue an ongoing R&D effort that leverages its intrinsically disordered protein technologies designed to explore the tumor microenvironment, leading to the identification of novel pathways that can be targeted with molecules to substantially influence "anti-tumoral" therapeutic responses. Ongoing nonclinical efforts have identified several novel candidates that may act as "Immune Checkpoint Inhibitors" alone or in combination with existing standard of care anti-PD-1 and CTLA-4 therapies to reverse CD8+ T cell functions, all with the aim of improving clinical outcomes across the vast range of cancer conditions. For more information, please visit www.dnxbio.com.
*Johnson & Johnson Enterprise Innovation Inc. is the legal entity to the agreement.
Media Contact:
Claude Gingras, CFO
Claude.Gingras@dnxbio.com
Related Links
- J&J Announcement of the Winners of the Lung Cancer QuickFire Award
https://www.newsfilecorp.com/redirect/XmpnIyDP
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52493
Topic: Press release summary
Source: DNX Biopharmaceuticals
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Mitsubishi Motors to Launch All-New Eclipse Sportback EV in the United States and Canada
Wednesday, June 10, 2026 10:15:00 PM
|
|
|
Bosch Home Comfort Group and Hitachi Group agree to collaborate on Intelligent connectivity and diagnosis solutions for Commercial Air Conditioning based on "HMAX for Buildings"
Wednesday, June 10, 2026 9:47:00 PM
|
|
|
Hitachi and Google Cloud expand strategic alliance to accelerate real-world deployment of physical AI through FDE and advanced cybersecurity solutions
Wednesday, June 10, 2026 9:18:00 PM
|
|
|
Toyota to participate in the "1000 Miglia Gran Turismo Experience 2026," a special program of the historic Italian rally, the 1000 Miglia
Wednesday, June 10, 2026 8:39:00 PM
|
|
|
Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives
June 10, 2026 20:30 HKT/SGT
|
|
|
Global Triumph: True IDC, Backed by CP Group and GIP, Wins 'Digital Infrastructure of the Year' at IJGlobal Awards, Set to Transform Thailand's Digital Economy with EEC Mega Data Center Project 
June 10, 2026 17:20 HKT/SGT
|
|
|
Fortinet launches Singapore NDR cloud PoP to strengthen threat detection across ASEAN
June 10, 2026 13:40 HKT/SGT
|
|
|
YesAsia Holdings Advances Dual-Engine Strategy with First YesStyle Concept Store in the US
June 10, 2026 11:27 HKT/SGT
|
|
|
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park
June 9, 2026 19:00 HKT/SGT
|
|
|
Haven Safety AI Announces Product Availability in Australia, Marking First International Expansion
June 9, 2026 19:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
